论文部分内容阅读
目的探讨力尔凡膀胱灌注预防浅表性膀胱尿路上皮癌术后复发。方法将152例浅表性膀胱尿路上皮癌术后患者随机分成两组。试验组:力尔凡+DDP+放疗;对照组:DDP+放疗。比较两组复发率、复发间隔时间,观察治疗前后T细胞亚群和白细胞总数。结果不同手术方式的复发率、复发间隔时间差异不显著(P>0.05);而试验组与对照组复发率、复发间隔时间比较均有显著性差异(P<0.05及P<0.01);试验组治疗前后NK细胞及CD4/CD8值比较有显著性差异(P<0.01),治疗后明显高于治疗前,对照组则无显著性差异;试验组治疗前后白细胞总数比较无显著性差异(P>0.05),对照组则有显著性差异(P<0.01),治疗后明显低于治疗前。结论力尔凡不但可以杀灭肿瘤细胞,而且有免疫复苏作用,在体内与其他免疫因子和化疗药物起协同作用,对膀胱尿路上皮癌不失为1种化疗配伍的安全、有效的药物。
Objective To investigate the prevention of bladder recurrence after superficial bladder urothelial carcinoma with Li Er Fan. Methods 152 cases of superficial urinary bladder cancer patients were randomly divided into two groups. Test group: Li Erfan + DDP + radiotherapy; control group: DDP + radiotherapy. The recurrence rate and recurrence interval were compared between the two groups, and the T cell subsets and leukocytes were observed before and after treatment. Results There was no significant difference in relapse rate and recurrence interval between different operation methods (P> 0.05), while the recurrence rate and recurrence interval in experimental group and control group were significantly different (P <0.05 and P <0.01) Before and after treatment, NK cells and CD4 / CD8 values were significantly different (P <0.01), after treatment was significantly higher than before treatment, no significant difference in the control group; test group before and after treatment the total number of leukocytes was no significant difference (P> 0.05), while there was significant difference in the control group (P <0.01), after treatment was significantly lower than before treatment. Conclusion Li Erfan can not only kill tumor cells, but also have the effect of immune resuscitation and synergistic effect with other immune factors and chemotherapy drugs in the body. It is a safe and effective drug for chemotherapy of bladder urothelial carcinoma.